Penumbra has received CE Mark approval in Europe for its THUNDERBOLT computer-assisted vacuum thrombectomy system, following FDA clearance in the United States last week. The device introduces modulated aspiration to the company's neuro thrombectomy portfolio and is designed to detect, fatigue, and completely ingest clots at the site of occlusion, potentially shortening procedure times and improving patient outcomes. THUNDERBOLT is the only CAVT device available for stroke treatment in both Europe and the United States, representing a first-of-its-kind advancement in acute ischemic stroke care. Penumbra shares edged down 0.2% to $318.21 on Monday following the announcement, though the company's international revenue rose 16.5% year over year in the first quarter of 2026 and accounted for 20.9% of total revenues. The company currently has a market capitalization of $12.44 billion, and the Zacks Consensus Estimate projects 2026 earnings growth of 32.3% and revenue growth of 13.3%.
Penumbra IncCE Mark approval for THUNDERBOLT stroke device, a first-of-its-kind advancement
Globus Medical
Integra LifeSciences Holdings
Phibro Animal Health Corporation